6.
Bensinger S, Bradley M, Joseph S, Zelcer N, Janssen E, Hausner M
. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008; 134(1):97-111.
PMC: 2626438.
DOI: 10.1016/j.cell.2008.04.052.
View
7.
Momtazi-Borojeni A, Ebrahimi Nik M, Jaafari M, Banach M, Sahebkar A
. Effects of immunization against PCSK9 in an experimental model of breast cancer. Arch Med Sci. 2019; 15(3):570-579.
PMC: 6524183.
DOI: 10.5114/aoms.2019.84734.
View
8.
Huang L, Li Y, Cheng Z, Lv Z, Luo S, Xia Y
. PCSK9 Promotes Endothelial Dysfunction During Sepsis Via the TLR4/MyD88/NF-κB and NLRP3 Pathways. Inflammation. 2022; 46(1):115-128.
DOI: 10.1007/s10753-022-01715-z.
View
9.
Kastelein J, Nissen S, Rader D, Hovingh G, Wang M, Shen T
. Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study. Eur Heart J. 2016; 37(17):1360-9.
PMC: 4852062.
DOI: 10.1093/eurheartj/ehv707.
View
10.
Jang H, Lee S, Yang J, Lee H, Shin D, Lee H
. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9. Eur Heart J. 2019; 41(2):239-252.
PMC: 6945527.
DOI: 10.1093/eurheartj/ehz566.
View
11.
Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Floter J
. NFATc1 controls the cytotoxicity of CD8 T cells. Nat Commun. 2017; 8(1):511.
PMC: 5593830.
DOI: 10.1038/s41467-017-00612-6.
View
12.
Reis Geovanini G, Libby P
. Atherosclerosis and inflammation: overview and updates. Clin Sci (Lond). 2018; 132(12):1243-1252.
DOI: 10.1042/CS20180306.
View
13.
Wicinski M, Zak J, Malinowski B, Popek G, Grzesk G
. PCSK9 signaling pathways and their potential importance in clinical practice. EPMA J. 2017; 8(4):391-402.
PMC: 5700013.
DOI: 10.1007/s13167-017-0106-6.
View
14.
Conze D, Krahl T, Kennedy N, Weiss L, Lumsden J, Hess P
. c-Jun NH(2)-terminal kinase (JNK)1 and JNK2 have distinct roles in CD8(+) T cell activation. J Exp Med. 2002; 195(7):811-23.
PMC: 2193724.
DOI: 10.1084/jem.20011508.
View
15.
Frostegard J
. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013; 11:117.
PMC: 3658954.
DOI: 10.1186/1741-7015-11-117.
View
16.
Lim S, Wei J, Nguyen T, Shi H, Su W, Palacios G
. Lipid signalling enforces functional specialization of T cells in tumours. Nature. 2021; 591(7849):306-311.
PMC: 8168716.
DOI: 10.1038/s41586-021-03235-6.
View
17.
Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F
. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004; 86(11):839-48.
DOI: 10.1016/j.biochi.2004.09.018.
View
18.
Khademi F, Momtazi-Borojeni A, Reiner Z, Banach M, Al-Rasadi K, Sahebkar A
. PCSK9 and infection: A potentially useful or dangerous association?. J Cell Physiol. 2017; 233(4):2920-2927.
DOI: 10.1002/jcp.26040.
View
19.
Ruan Q, Kameswaran V, Zhang Y, Zheng S, Sun J, Wang J
. The Th17 immune response is controlled by the Rel-RORγ-RORγ T transcriptional axis. J Exp Med. 2011; 208(11):2321-33.
PMC: 3201209.
DOI: 10.1084/jem.20110462.
View
20.
Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J
. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372(16):1500-9.
DOI: 10.1056/NEJMoa1500858.
View